SLN
OTC MARKETS · Biotechnology
Silence Therapeutics PLC
$11.20
+0.02 (+0.18%)
Financial Highlights (FY 2026)
Revenue
14.24M
Net Income
-30,159,021
Gross Margin
37.8%
Profit Margin
-231.4%
Rev Growth
+315.5%
D/E Ratio
2.02
Income Statement
| FY 2026 | |
|---|---|
| Revenue | 14.24M |
| Gross Profit | 5.39M |
| Operating Income | -39,552,197 |
| Net Income | -30,159,021 |
| Gross Margin | 37.8% |
| Operating Margin | -277.7% |
| Profit Margin | -231.4% |
| Rev Growth | +315.5% |
Balance Sheet
| FY 2026 | |
|---|---|
| Total Debt | 233.25M |
| Total Equity | 115.43M |
| D/E Ratio | 2.02 |
Cash Flow
| FY 2026 | |
|---|---|
| EBITDA | -33,794,946 |
| Free Cash Flow | — |